Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy
暂无分享,去创建一个
E Provenzano | H Earl | E. Provenzano | S. Pinder | H. Earl | S. Pinder | I. Ellis | I O Ellis | S E Pinder | I. Ellis
[1] A. Makris,et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer , 2004, British Journal of Cancer.
[2] F. Penault-Llorca,et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.
[3] P. Hurteloup,et al. Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .
[4] R. Hildenbrand,et al. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer , 2005, Virchows Archiv.
[5] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Al-Sobhi,et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. , 2002, American journal of surgery.
[7] A. Luini,et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.
[8] F. Penault-Llorca,et al. Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy , 2002, Breast Cancer Research and Treatment.
[9] F. Penault-Llorca,et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? , 2003, British Journal of Cancer.
[10] Z. Baloch,et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.
[11] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Hortobagyi,et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[13] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[14] J. Pierga,et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. , 2003, European journal of cancer.
[15] C. Sung,et al. Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy , 2005, Breast Cancer.
[16] B. Cady,et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. , 2003, American journal of surgery.
[17] L. Newman,et al. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome , 2003, Annals of Surgical Oncology.
[18] M. Brizzi,et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. , 1996, Anticancer research.
[19] A. Satterfield,et al. TREATMENT , 1924, California and western medicine.
[20] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[21] A. Schneeweiss,et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy , 2004, Anti-cancer drugs.
[22] Carder. Typing breast cancer following primary chemotherapy , 1999, Histopathology.
[23] T E Walsh,et al. Reporting results. , 1969, Archives of otolaryngology.